AgingResearch.NewsJoin free

Nuevocor

CompanySingapore

Nuevocor develops one asset, in phase 1 (NVC-001 in LMNA dilated cardiomyopathy). Mostly gene therapy acting on LMNA; based in Singapore.

1
Asset
Furthest stage
Phase 1
0
Trials
0
Signals

Pipeline

1

  • NVC-001

    AAV gene therapy targeting mechanobiological pathways to rescue nuclear envelope strain in LMNA cardiomyopathy

    Phase 1, Gene therapy, LMNA, LMNA dilated cardiomyopathy

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Similar companies4

Intelligence